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Abstract 
	
Background:	 Temozolomide	 has	 shown	 a	 significant	 anti-proliferative	 activity	 on	 adrenocortical	
cancer	(ACC)	cells	 in	vitro.	On	the	basis	of	these	results	the	drug	was	prescribed	as	second/third	
line	in	advanced	metastatic	ACC	patients	in	some	referral	centers	in	Italy.	 
Methods:	We	retrospectively	collected	anagraphic,	clinical	and	pathological	data	of	advanced	ACC	
patients	with	disease	progression	to	standard	chemotherapy	plus	mitotane	who	were	treated	with	
temozolomide	at	the	dose	of	200	mg/m2	die	(g:	1	->	5	q28)	 in	4	 italian	Institutions.	The	primary	
end-point	was	 the	 clinical	 benefit,	 defined	 as	 objective	 response	or	 disease	 stabilization	 after	 3	
months.	Secondary	endpoints	were	overall	survival	(OS),	progression	free	survival	(PFS)	and	drug	
safety.	 
Results:	Twenty-eight	patients	have	been	included	in	the	study.	Ten	patients	(35.8%,	95%	CI	17.8-
53.8)	 obtained	 a	 clinical	 benefit	 from	 temozolomide	 treatment.	 In	 particular,	 1	 patient	 had	 a		
complete	response,	5	patients	a	partial	 response	and	4	patients	stable	disease.	Median	PFS	was	
3.5	 months	 and	 median	 OS	 7.2	 months.	 Disease	 response	 was	 more	 frequently	 observed	 in	
patients	 with	 metilation	 of	 O6-methylguanine-DNA	 methyltransferase	 (MGMT)	 gene.	
Temozolomide	 therapy	 was	 well	 tolerated	 and	 most	 toxicities	 were	 limited	 to	 grade	 G1-2	
according	to	WHO	criteria.	
Conclusion:	Temozolomide	appeared	to	be	active	in	the	management	of	advanced	ACC	patients.	
The	clinical	benefit	obtained,	however,	was	short	lived	and	the	prognosis	of	treated	patients	was	
poor.		 
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Introduction 
Adrenocortical	 carcinoma	 (ACC)	 is	 a	 rare	 and	 aggressive	 tumor	with	 an	 incidence	 of	 0.5-2	 new	
cases	 per	 million	 population	 per	 year	 (1).	 Surgery	 is	 the	 mainstay	 of	 therapy	 but	 a	 significant	
proportion	 of	 patients	 are	 not	 operable	 at	 diagnosis,	 and	 most	 patients	 radically	 resected	 are	
destined	to	relapse	within	the	first	2	years	(1).	This	is	the	reason	why	adjuvant	mitotane	therapy	is	
recommended	by	recent	guidelines	(2,3),	despite	the	low	evidence	of	efficacy	(1-6). 
The	standard	systemic	treatment	for	advanced/metastatic	ACC	patients,	not	eligible	to	surgery,	is	
mitotane.	 This	 drug	 is	 administered	 either	 alone	 (1),	 or	 in	 combination	 with	 Etoposide,	
Doxorubicin	and	Cisplatin	 (EDP-M	 regimen)	 (7).	 The	efficacy	of	 the	EDP-M	 regimen,	however,	 is	
limited	as	shown	by	the	results	of	a	randomized	clinical	trial	reporting	a	disease	response	in	about	
25%	 of	 treated	 patients	 with	 a	 median	 survival	 of	 14	 months	 (8).	 No	 effective	 therapies	 are	
available	 for	patients	with	disease	progression	after	EDP-M	(9).	The	combination	of	gemcitabine	
and	 capecitabine,	 which	 is	 recommended	 by	 currently	 available	 guidelines	 (2,3),	 is	 poorly	
efficacious	(10,11).	Other	treatment	strategies,	 including	modern	molecular	target	therapies	and	
immunotherapy	(12,13,14),	failed	to	demonstrate	significant	activity.	New	therapeutic	options	are	
therefore	urgently	needed.	 
Temozolomide	is	an	alkylating	drug	initially	used	in	the	treatment	of	brain	tumors	(15).	The	drug	
has	been	demonstrated	to	be	efficacious	also	in	the	management	of	neuroendocrine	tumors	(16)	
and	 malignant	 pheochromocytoma/paraganglioma	 (17).	 Creemers	 and	 colleagues	 recently	
published	 a	 pre-clinical	 study	 exploring	 the	 activity	 of	 temozolomide	 in	 ACC	 cells	 in	 vitro.	 Their	
data	showed	that	the	drug	has	cytotoxic	and	cytostatic	effects	through	a	strong	inhibition	of	cell	
growth,	 apoptosis	 and	cell	 cycle	arrest	 (18).	Moreover,	 a	 slight	 relationship	was	 found	between	
the	 in	 vitro	 cytotoxicity	 of	 temozolomide	 and	 the	 epigenetic	 silencing	 of	 the	 MGMT	 (O6-
methylguanine-DNA	 methyltransferase)	 DNA-repair	 (MGMT)	 gene,	 which	 is	 associated	 with	
temozolomide	 efficacy	 in	 patients	 with	 glioblastoma	 (19-21)	 and	 advanced	 neuroendocrine	
tumors	(16).		
Given	 these	 results	 and	 the	 limited	 therapeutic	 strategies	 available	 in	 the	 management	 of	
advanced	ACC,	 some	 reference	 centers	 for	 this	 rare	 disease	 in	 Italy	 used	 temozolomide	 in	 ACC	
patients	 with	 disease	 progression	 to	 standard	 therapies.	 In	 this	 study,	 we	 did	 a	 retrospective	
assessment	of	temozolamide	activity	and	toxicity	in	this	peculiar	clinical	setting.	 
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Patients	and	methods 
Study	design	and	patient	characteristics	 
This	 is	 a	 multicentric,	 retrospective	 study.	 Twenty-eight	 consecutive	 ACC	 patients	 treated	 with	
temozolomide	 from	 January	 2016	 to	 January	 2018	 at	 four	 Italian	 Institutions	were	 included.	All	
patients	met	the	following	eligibility	criteria:	age	>18	years;	Eastern	Cooperative	Oncology	Group	
(ECOG)	 performance	 status	 0–2;	 life	 expectancy	 of	 at	 least	 3	months;	 pathological	 diagnosis	 of	
ACC;	locally	advanced	or	metastatic	disease	not	suitable	for	surgery;	at	 least	one	unidimensional	
(RECIST	criteria)	measurable	lesion;	adequate	bone	marrow	reserve	(neutrophils	>1500/mm3	and	
platelets	 >100	 000/mm3,	 hemoglobin	 >9.0	 g/dl);	 total	 bilirubin	 <1.5	 times	 the	 upper	 limit	 of	
normal;	 serum	 creatinine	 <1.5	 the	 upper	 limit	 of	 normal;	 effective	 contraception	 in	
premenopausal	 female	 and	 male	 patients;	 written	 informed	 consent.	 Exclusion	 criteria	 were	
history	 of	 prior	malignancy,	 except	 for	 cured	 non	melanoma	 skin	 cancer,	 cured	 in	 situ	 cervical	
carcinoma,	or	other	treated	malignancies	with	no	evidence	of	disease	for	at	 least	3	years;	active	
clinically	 serious	 infections	 (greater	 than	 grade	 2	 National	 Cancer	 Institute	 -	 Common	 Toxicity	
Criteria	 (NCI-CTC)	 version	 3.0);	 symptomatic	 metastatic	 brain	 or	 meningeal	 tumors;	 seizure	
disorder	 requiring	 medication	 (i.e.	 steroids	 or	 antiepileptics);	 decompensated	 heart	 failure	
(ejection	 fraction	 >45%);	myocardial	 infarction	 or	 revascularization	 procedure	 during	 the	 last	 6	
months;	 unstable	 angina	pectoris;	 uncontrolled	 cardiac	 arrhythmia;	 hypertension	not	 controlled	
by	 medications;	 pregnant	 or	 breast-feeding	 patients;	 treatment	 with	 temozolomide;	 other	
anticancer	chemotherapy	or	 immunotherapy	during	 the	study	or	within	4	weeks	of	 study	entry;	
radiotherapy	during	study	or	within	3	weeks	of	study	start	(palliative	radiotherapy	was	allowed);	
major	surgery	within	4	weeks	of	study	start;	concomitant	treatment	with	another	investigational	
drug.	 The	 off	 label	 use	 of	 temozolomide	 was	 authorized	 by	 the	 hospitals	 of	 each	 participating	
institutions.	 The	 retospective	 study	was	 approved	 by	 the	 Ethical	 Review	 Board	 of	 ASST-Spedali	
Civili	in	Brescia	(n.).	 
Treatment	 consisted	 in	 temozolomide	at	 the	planned	dosage	of	200	mg/m2	die	 (g:	1	 ->	5	q28).	
Maintenance	 of	 previous	 mitotane	 treatment	 was	 allowed	 but	 not	 mandatory	 and	 blood	 drug	
levels	monitored.	Disease	 re-staging	 by	 CT	 scan	 and/or	MRI	was	 performed	every	 3	 cycles.	 The	
following	 demographic,	 clinical	 and	 pathological	 data	were	 collected:	 sex,	 age,	medical	 history,	
physical	examination,	performance	status,	routine	laboratory	tests,	endocrine	work-up,	chest	and	
abdominal	 CT	 scan,	 other	 imaging	 data	 (i.e.	 brain	 CT,	magnetic	 resonance	 imaging,	 bone	 scan)	
performed	at	baseline	and	during	temozolomide	treatment.	 
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The	study	primary	endpoint	was	the	clinical	benefit	of	the	therapy,	defined	as	disease	response	or	
stabilization	 at	 CT	 scan	 after	 3	 months,	 using	 RECIST	 criteria	 version	 1.1.	 Secondary	 endpoints	
were	the	evaluation	of	progression-free	survival	(PFS),	overall	survival	(OS)	and	treatment	toxicity.	
PFS	 was	 defined	 as	 the	 time	 elapsing	 from	 the	 beginning	 of	 the	 treatment	 until	 disease	
progression	 or	 death	 whatever	 event	 occurred	 first.	 Non-progressing	 patients	 still	 alive	 were	
consored	 at	 the	 last	 follow-up	 examination.	 Overall	 survival	 was	 defined	 as	 the	 time	 interval	
between	the	date	of	treatment	start	and	the	date	of	death	from	any	cause	or	the	last	known	alive	
date.	The	mENSAT	classification	and	GRAS	parameters	(22),	as	defined	by	grade	(Weiss	score	<6	or	
>6	 or	 Ki67	 <20%	or	 >20%),	 resection	 status	 of	 the	 primary,	 age	 younger	 than	 or	 older	 than	 50	
years,	and	absence	or	presence	of	tumor	related	or	hormone-related	symptoms	at	diagnosis,	were	
used	to	assess	prognosis.	The	CTCAE	v4.03	score	was	used	to	assess	toxicity.	 
	
Assessment	of	MGMT	promoter	methylation	in	tumor	samples	 
	
As	 ancillary	 study,	 we	 evaluated	 the	 predictive	 role	 of	 MGMT	 (O6-methylguanine–DNA	
methyltransferase)	 promoter	 methylation	 in	 a	 patient	 subset	 included	 in	 this	 study	 for	 which	
tumor	samples	were	available.	MGMT	promoter	methylation	status	was	performed	by	means	of	
pyrosequencing	 technique.	 Ten	 methylated	 CpG	 sites	 were	 analyzed,	 located	 in	 the	 promoter	
region	(NG_052673.1-chr10:131,265,507-131,265,556)	of	MGMT	gene	exon	1	and	involved	in	the	
regulation	of	gene	expression.	Genomic	DNA	(gDNA)	was	automated	obtained	from	FFPE	tissues	
after	manual	microdissection,	 for	neoplastic	 cell	 enrichment	 (at	 least	50%	of	 tumor	 cells),	 using	
the	Maxwell®	RSC	instrument	and	tissue	DNA	Kit	(Promega	s.r.l,	Milan,	Italy).	A	total	of	500ng	of	
gDNA	was	modified	by	bisulfite	conversion	using	a	commercial	available	and	certified	CE-IVD	kit	
(MGMT	 plus,	 Diatech	 pharmacogenetics,	 Ancona,	 Italy)	 following	 manufacturer’s	 instructions.	
Sequencing	analysis	was	performed	on	PyroMark	Q96MA	apparatus	 (Biotage,	Uppsala,	 Sweden)	
with	PCR	and	sequencing	primers	supplied	in	the	MGMT	plus	kit	according	to	the	manufacturer’s	
instructions.	
Analysis	 	of	methylation	 (corretto?	Data	analisi	è	nel	capitol	seguente)	was	performed	using	the	
PyroMarkCpG	software	(Biotage),	obtaining	a	mean	pencentage	of	the	ten	CpG	methylated	islands	
for	 each	 case.	 A	 cut-off	 of	 5%	 (mean	 of	 the	 CpG	 islands)	 of	 methylation	 was	 used	 to	 define	
“methylated”	 (>5%)	 and	 “unmethylated”	 (<	 or	 =5%)	 samples.	 Methylated	 and	 un-Methylated	
controls	were	properly	used	to	take	control	of	all	workflow.	
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Statistical	analysis 
Descriptive	statistics	were	used	to	analyze	the	patient	clinical	characteristics.	Differences	between	
categorical	variables	were	assessed	by	a	chi-square	or	the	Fisher	test	when	indicated.	The	PFS	and	
OS	curves	were	calculated	with	the	Kaplan–Meier	method	and	compared	with	the	 log-rank	test.	
The	 primary	 end	 point	 of	 the	 study	 was	 to	 estimate	 the	 activity	 of	 the	 therapy	 in	 terms	 of	
proportion	 of	 patients	 attaining	 a	 clinical	 benefit.	 With	 28	 patients	 recruited,	 this	 study	 has	 a	
potency	 of	 80%	 to	 refuse	 a	 clinical	 benefit	 rate	 of	 15%	 (p0)	 and	 to	 assess	 the	 activity	 of	 the	
therapy	as	a	clinical	benefit	rate	of	40%;	given	an	alpha	error	of	0.05.	Statistical	significance	was	
set	at	p	<	0.05.	SPSS	v17.0	software	was	used	for	the	statistical	analyses	(SPSS	Inc.,	Chicago,	IL). 
	
Results 
Patient	characteristics 
The	characteristics	of	the	28	enrolled	patients	are	summarized	in	Table	1.	Median	age	at	baseline	
was	54	years	(range	31-72).	Thirteen	patients	(46.4%)	had	a	hormone-secreting	tumor	at	diagnosis	
and	10	of	 them	(35.7%)	had	Cushing	syndrome.	Twenty-six	patients	 (92.8%)	underwent	primary	
surgery	as	the	first	treatment	and	20	of	them	(71.4%)	obtained	a	complete	resection	(R0).	Median	
disease	 free	 survival	of	 surgical	 treated	patients	was	19.9	months	 (range	5-49).	 Twelve	patients	
(42.9%)	received	post-operative	adjuvant	mitotane.	 
Cisplatin	alone	or	the	EDP	combination	regimen,	both	administered	in	association	with	mitotane	
were	 the	 first	 line	 cytotoxic	 therapies	 adopted	 after	 the	 diagnosis	 of	 metastatic	 disease.	 At	
baseline	 conditions,	 before	 starting	 temozolomide,	 the	 majority	 of	 patients	 (71.4%)	 had	 a	
performance	status	≤1.	According	to	mENSAT	classification,	16	patients	(57.1%)	had	a	stage	IV-A	
disease,	9	(32.2%)	stage	IV-B,	3	(10.7%)	stage	IV-C.	GRAS	parameters	were	favorable	in	6	(21.4%),	
unfavorable	in	9	(32.2%)	and	pejorative	in	13	(46.4%)	patients. 
	
	
Treatment	administered	and	activity 
Temozolomide	 was	 administered	 as	 second	 line	 in	 9	 patients	 (32.2%),	 third	 line	 therapy	 in	 16	
patients	(57.1%)	and	fourth	line	approach	in	3	(10.7%).	All	patients	maintained	previous	mitotane	
therapy	and	the	drug	levels	were	within	the	therapeutic	range	in	10	(35.7%)	of	them. 
The	 median	 number	 of	 temozolomide	 cycles	 was	 4	 (range	 2-16).	 One	 patient	 (3.6%)	 obtained	
complete	clinical	response	evaluated	by	RECIST	1.1	criteria,	while	partial	response	was	observed	in	
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5	 patients	 (17.9%),	 and	 4	 patients	 (14.3%)	 obtained	 disease	 stabilization.	 However,	 18	 patients	
(64.2%)	 had	 disease	 progression.	 The	 overall	 response	 rate	was	 21.5%	 (95%	 CI	 6.5-27.5)	 and	 a	
clinical	benefit	was	obtained	in	10	patients	(35.8%)	(95%	CI	17.8-53.8)	(Table	2).	 
At	 disease	 progression,	 further	 chemotherapy	 was	 administered	 in	 6	 patients;	 in	 particular,	 4	
patients	 received	 gemcitabine	 and	 capecitabine	 whereas	 2	 patients	 received	 cisplatin	 as	 single	
agent.		
	
Patient	outcome 
Median	PFS	was	3.5	months	 (range	1.2-24.2)	 (Figure	1a)	 and	OS	was	7.2	months	 (range	2-24.2)	
(Figure	1b).	No	significant	difference	in	PFS	was	seen	stratifying	patients	on	the	basis	of	whether	
they	 received	 temozolomide	 as	 second	 or	 further	 line	 of	 treatment	 (p=0.26).	 In	 addition,	 the	
attainment	of	a	clinical	benefit	did	not	have	any	positive	impact	on	OS:	median	8.1	(range	..-..)	in	
patients	 attaining	 a	 clinical	 benefit	 vs	 7.1	 months	 (range	 ..-..)	 in	 those	 who	 did	 not	 (p=0.77).	
Additional	analyses	were	done	to	explore	the	potential	prognostic	significance	of	several	patient	
and	tumor	characteristics.	The	patients	with	ECOG	PS	0	had	longer	PFS	and	OS	than	those	with	PS	
1	or	2	(p	0.008	and	p	0.003	respectively)	(data	not	shown).	Favourable	GRAS	score	was	associated	
with	a	longer	PFS	(median	8.4	months)	and	OS	(median	12.2	months)	than	unfavorable/pejorative	
GRAS	 (PFS:	 4.2	 months	 and	 OS:	 6.9	 months),	 although	 these	 differences	 were	 not	 statistically	
significant	(p=0,16	and	p=0.17,	respectively)(Figure	2a,	Figure	2b).	PFS	and	OS	curves	were	similar	
in	 patients	 with	 unfavorable	 and	 pejorative	 GRAS	 score	 (Figure	 2).	 However,	 mENSAT	 and	 the	
combination	 of	 mENSAT	 with	 GRAS	 failed	 to	 be	 associated	 with	 either	 PFS	 (p=0.33	 and	 0.39,	
respectively)	 or	 OS	 (p=0.97,	 0.83	 respectively).	 Stratifying	 patients	 according	 to	 circulating	
mitotane	levels,	PFS	and	OS	were	6.6	months	and	12.6	months,	respectively	in	patients	in	which	
blood	 mitotane	 was	 within	 the	 therapeutic	 range	 (14-20	 mcg/L)	 while	 they	 were	 3.5	 and	 6.8	
months	respectively	in	those	in	which	the	drug	was	below	14	mcg/L	(p=	0.45	for	PFS,	p=	0.36	for	
OS)	(Figure	3).		
 
Treatment	toxicity 
Patients	 were	 evaluated	 after	 each	 cycle	 with	 both	 clinical	 examination	 and	 blood	 chemistry	
(complete	 blood	 count,	 liver	 and	 renal	 function).	 The	 observed	 temozolomide	 toxicities	 are	
summarized	 in	Table	3.	As	expected,	nausea	and	vomiting	were	 the	most	 frequent	 side	effects,	
occurring	in	35.8%	and	25%	of	patients,	respectively.	These	symptoms	were	classified	as	grade	3	in	
14.3%	and	10.7%	of	patients,	 respectively.	 Liver	 toxicity	was	observed	 in	25%	of	patients,	being	
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grade	 3	 in	 7.2%	 of	 cases.	 Only	 1	 patient	 (3.6%)	 developed	 grade	 3	 neutropenia.	 The	 other	
observed	 toxicities	were:	 renal	 impairment	 and	 thrombocytopenia,	 involving	 25%	 and	 21.4%	of	
patients,	respectively.	A	one-week	delay	in	the	start	of	a	new	cycle	was	needed	in	12	patients	due	
to	toxicity,	whereas	no	dose	reduction	was	prescribed.		
	
MGMT	status	and	relevant	correlation	with	drug	activity 
	
MGMT	status	was	evaluated	in	15	patients,	eight	of	them	showing	MGMT	promoter	methylation.	
In	 the	 methylated	 MGMT	 group,	 4	 patients	 out	 of	 8	 (50.0%)	 obtained	 a	 disease	 response,	 in	
particular,	 1	 had	 a	 complete	 response	 and	 3	 had	 a	 partial	 response.	 Conversely,	 in	 the	 non-
methylated	 MGMT	 group,	 only	 1	 patient	 out	 of	 7	 (14.3%)	 had	 a	 partial	 response,	 whereas	 1	
patient	 (14.3%)	 had	 a	 stable	 disease	 and	 the	 others	 had	 progressive	 disease	 (Table	 4).	 No	
differences	in	PFS	or	OS	were	observed	comparing	patients	with	(median	..	months	[range	..	-	..)	or	
without	(median	..	months	[range	..	-	..)	MGMT	methylation	(p	0.08,	p	0.45	respectively). 
	
	
Discussion 
Alkylating	agents	have	been	shown	some	activity	in	ACC.	Our	group	has	observed	a	clinical	benefit	
of	the	administration	of	oral	cyclophosphamide	on	a	metronomic	schedule	in	2	heavily	pre-treated	
patients	(24).	Moreover,	streptozotocyn	(Sz)	demonstrated	a	response	rate	of	35%	in	40	advanced	
ACC	assessed	retrospectively	in	Sweden	(23).	On	the	basis	of	these	results,	the	association	Sz	was	
considered	 as	 the	 best	 treatment	 to	 be	 tested	 against	 EDP	 in	 the	 FIRM-ACT	 trial	 (8).	 Since	 this	
combination	appeared	inferior	to	EDP,	Sz	is	not	generally	used	as	first	line	approach.	However,	it	is	
still	recommended	as	a	possible	second	line	therapy	by	currently	available	guidelines	(2,3).		
Due	 to	 the	 demonstrated	 activity	 of	 alkylating	 agents	 in	 the	 management	 of	 ACC	 and	 the	
preclinical	findings	showing	that	temozolomide	exerted	a	potent	antitumor	effect	on	ACC	cells	 in	
vitro	(..),	4	Italian	reference	centers	obtained	the	authorization	for	the	off	label	administration	of	
the	 drug	 at	 dose	 of	 200	 mg/m2	 die	 in	 ACC	 patients	 with	 disease	 progression	 after	 first	 line	
chemotherapy	with	cisplatin	containing	regimens	plus	mitotane.	In	this	retrospective	evaluation	of	
these	patients,	temozolomide	was	as	whole	well	tolerated	and	toxicities	were	manageable.	
Indeed	the	drug	showed	an	appreciable	activity,	since	the	diseases	responses	according	to	RECIST	
criteria	 observed	 in	 20%	of	 patients	 appears	 superior	 to	 the	 4%	 response	 rate	 obtained	 by	 the	
association	gemcitabine	plus	capecitabine,	a	recommended	second	 line	regimen	in	ACC	(10,	11).	
The	 clinical	 benefit	 (clinical	 response	 and	 stable	 disease)	 of	 35%	 obtained	 by	 temozolomide,	
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however,	was	 comparable	 to	 that	 reported	 by	 the	 association	 of	 gemcitabine	 and	 capecitabine	
(10,	11).	However,	the	responses	obtained	 in	this	study	were	short-lived	and,	more	 importantly,	
the	 disease	 response	 did	 not	 influence	 the	 patients	 survival,	 which	 was	 only	 of	 7	 months	 on	
average.	 This	 finding	 is	 in	 contrasts	 to	what	 it	 is	 commonly	observed	 in	 chemotherapy	 trials, in	
which	 disease	 response	 usually	 discriminates	 two	 patient	 populations	 with	 different	 prognosis	
(25).	
In	these	pre-treated	ACC	patients,	poor	performance	status	was	the	strongest	negative	prognostic	
factor,	whereas	mENSAT	 stage	 failed	 to	 correlate	with	PFS	and	overall	 survival.	 Favorable	GRAS	
score	was	associated	with	better	outcome	in	terms	of	PFS	and	OS	without	attaining	the	statistical	
significance	 than	either	unfavorable	and	pejorative	 scores,	which	 showed	similar	prognosis.	 The	
low	number	of	patients	enrolled	conferred	 to	our	 series	a	 low	potency	 to	 test	 these	prognostic	
factors.		
It	was	found	 in	other	malignancies	that	the	therapeutic	benefit	of	temozolomide	depends	on	 its	
ability	to	alkylate/methylate	DNA.	This	methylation	damages	the	DNA,	thus	triggering	cell	death	by	
apoptosis.	Primary	resistance	to	 temozolomide	 in	glioblastoma	and	 in	neuroendocrine	tumors	 is	
often	directly	related	to	high	MGMT	expression	(16,19).	So	MGMT	inactivation	by	metylation	is	a	
marker	 of	 temozolomide	 tumor	 cell	 sensitivity.	 In	 our	 series,	 we	 were	 able	 to	 assess	 MGMT	
expression	 in	 15	 cases.	 Despite	 the	 low	 numbers,	 the	 objective	 response	 rate	 was	 of	 50%	 in	
methylated	ACC	vs	14%	 in	non-methylated	ACC,	and	this	 finding	 is	consistent	with	 the	potential	
role	of	MGMT	inactivation	in	favoring	temozolomide	cytotoxicity	in	ACC	patients.	
In	conclusion,	temozolomide,	administered	as	second	line	approach	in	ACC,	 induced	a	significant	
tumor	 shrinkage	 in	 about	 one	out	 of	 five	 patients.	Despite	 this	 non-negligible	 activity,	 the	drug	
failed	to	demonstrate	to	be	efficacious,	since	the	responses	observed	were	short	lived	and	did	not	
influence	patient	survival.	On	the	basis	of	these	data,	we	believe	that	temozolomide	should	not	be	
recommended	as	second	line	therapy	in	unselected	ACC	patients.	However,	temozolamide	could	
be	 a	 potential	 option	 in	 patients	 with	 good	 PS	 bearing	 MGMT	 methylated	 ACC,	 and	 this	 may	
represent	a	first	step	toward	a	personalized	medicine	approach	in	advanced	ACC.				
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